Using yeast to study resistance to topoisomerase II-targeting drugs
- PMID: 8070029
- DOI: 10.1007/BF00684857
Using yeast to study resistance to topoisomerase II-targeting drugs
Abstract
We have developed a system utilizing the yeast Saccharomyces cerevisiae to probe the mechanism of action of anti-topoisomerase II drugs. This system has enabled us to dissect the mechanism of action of these agents. By inducing the overexpression of yeast topoisomerase II or by reducing the level of activity using temperature-sensitive mutations in topoisomerase II, we have demonstrated that conversion of topoisomerase II to a cellular poison plays a critical role in cell killing. We have also constructed other mutations in the yeast TOP2 gene that are resistant to etoposide and amsacrine and determined the DNA sequences for several of the drug-resistant alleles. The mutations that confer drug resistance map to several regions of the TOP2 gene. A mutation of particular interest changes Ser741 to Trp. This mutation results in hypersensitivity to etoposide but does not alter sensitivity to other agents such as mAMSA. We suggest that this mutation defines a site on the TOP2 protein that is involved in drug:protein interactions.
Similar articles
-
The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.J Biol Chem. 1993 Sep 5;268(25):18586-92. J Biol Chem. 1993. PMID: 8395511
-
Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.Cancer Res. 1994 Apr 1;54(7):1795-800. Cancer Res. 1994. PMID: 8137294
-
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.J Biol Chem. 1995 Sep 1;270(35):20359-64. doi: 10.1074/jbc.270.35.20359. J Biol Chem. 1995. PMID: 7657608
-
DNA topoisomerase II mutations and resistance to anti-tumor drugs.Bioessays. 1995 Sep;17(9):767-74. doi: 10.1002/bies.950170906. Bioessays. 1995. PMID: 8763829 Review.
-
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.Cancer Chemother Pharmacol. 1994;34 Suppl:S19-25. doi: 10.1007/BF00684859. Cancer Chemother Pharmacol. 1994. PMID: 8070023 Review.
Cited by
-
mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.Nucleic Acids Res. 2006 Mar 20;34(5):1597-607. doi: 10.1093/nar/gkl057. Print 2006. Nucleic Acids Res. 2006. PMID: 16549872 Free PMC article.
-
Targeting DNA Topoisomerase II in Antifungal Chemotherapy.Molecules. 2022 Nov 11;27(22):7768. doi: 10.3390/molecules27227768. Molecules. 2022. PMID: 36431868 Free PMC article. Review.
-
Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.Biochemistry. 2008 Apr 15;47(15):4501-9. doi: 10.1021/bi702019z. Epub 2008 Mar 21. Biochemistry. 2008. PMID: 18355043 Free PMC article.
-
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.Clin Microbiol Rev. 1999 Oct;12(4):583-611. doi: 10.1128/CMR.12.4.583. Clin Microbiol Rev. 1999. PMID: 10515904 Free PMC article. Review.
-
Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.J Biol Chem. 2008 Oct 24;283(43):29239-50. doi: 10.1074/jbc.M804058200. Epub 2008 Aug 22. J Biol Chem. 2008. PMID: 18723844 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Molecular Biology Databases
Miscellaneous